BRIEF-Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability

Reuters2024-11-25

Nov 25 (Reuters) - Enveric Biosciences Inc :

* ENVERIC BIOSCIENCES PRECLINICAL PHARMACOKINETIC STUDIES OF EB-003 SUPPORT ORAL BIOAVAILABILITY, DEMONSTRATE BRAIN PENETRATION, AND SHOW NO EVIDENCE OF HALLUCINATION-LIKE BEHAVIOR

* ENVERIC BIOSCIENCES : PLANS TO SUBMIT EB-003 IND APPLICATION TO FDA IN H2 OF 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486832087?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-25 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486832087","market":"us","top_or_hot":-1,"title":"BRIEF-Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability","media":"Reuters","content":"<html><body><p>Nov 25 (Reuters) - <a href=\"https://laohu8.com/S/ENVB\">Enveric Biosciences</a> Inc   :</p><p>   * ENVERIC BIOSCIENCES PRECLINICAL PHARMACOKINETIC STUDIES OF EB-003 SUPPORT ORAL BIOAVAILABILITY, DEMONSTRATE BRAIN PENETRATION, AND SHOW NO EVIDENCE OF HALLUCINATION-LIKE BEHAVIOR</p><p>   * ENVERIC BIOSCIENCES : PLANS TO SUBMIT EB-003 IND APPLICATION TO FDA IN H2 OF 2025</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-25 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 25 (Reuters) - Enveric Biosciences Inc   :   * ENVERIC BIOSCIENCES PRECLINICAL PHARMACOKINETIC STUDIES OF EB-003 SUPPORT ORAL BIOAVAILABILITY, DEMONSTRATE BRAIN PENETRATION, AND SHOW NO EVIDENCE ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4077","symbol_name":"互动媒体与服务","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2486832087","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486832087","pubTimestamp":1732544110,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 25  - Enveric Biosciences Inc   :   * ENVERIC BIOSCIENCES PRECLINICAL PHARMACOKINETIC STUDIES OF EB-003 SUPPORT ORAL BIOAVAILABILITY, DEMONSTRATE BRAIN PENETRATION, AND SHOW NO EVIDENCE OF HALLUCINATION-LIKE BEHAVIOR   * ENVERIC BIOSCIENCES : PLANS TO SUBMIT EB-003 IND APPLICATION TO FDA IN H2 OF 2025Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4077":"互动媒体与服务","BK4108":"电影和娱乐","BK4007":"制药","EB":"Eventbrite Inc.","ENVB":"Enveric Biosciences"},"translate_title":"Brief-Enveric Biosciences EB-003的临床前药代动力学研究支持口服生物利用度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EB":1,"ENVB":1},"content_text":"Nov 25 (Reuters) - Enveric Biosciences Inc   :   * ENVERIC BIOSCIENCES PRECLINICAL PHARMACOKINETIC STUDIES OF EB-003 SUPPORT ORAL BIOAVAILABILITY, DEMONSTRATE BRAIN PENETRATION, AND SHOW NO EVIDENCE OF HALLUCINATION-LIKE BEHAVIOR   * ENVERIC BIOSCIENCES : PLANS TO SUBMIT EB-003 IND APPLICATION TO FDA IN H2 OF 2025Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486832087"}